Observational studyBMC pregnancy and childbirth2025
Enhancing Crohn's disease management during pregnancy: innovations in therapeutic approaches and cutting-edge monitoring practices.
Observational study in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the current practices and highlight the importance of ongoing innovation in managing Crohn’s disease (CD) during pregnancy.
methodsA prospective observational study was conducted at Kanuni Sultan Suleyman Training and Research Hospital, encompassing patients managed from 2023 to 2024. The study included 43 pregnant women diagnosed with Crohn’s disease who were monitored throughout the prepartum and postpartum periods. Clinical data regarding disease duration, medication use, intestinal surgery history, maternal complications, and neonatal outcomes were collected and analyzed. Key variables included the need for a neonatal intensive care unit (NICU), gestational age at delivery, mode of delivery, and neonatal birth weight.
resultsA cohort of 43 patients with Crohn’s disease was analyzed for maternal and neonatal outcomes. The median age of the cohort was 33.7 ± 4.8 years, with a median disease duration of 6.8 ± 3.9 years. Vaginal delivery (VD) was achieved in 51.2% of cases, while 48.8% required a cesarean section. Assisted reproductive techniques (ART) were used in 9.4% of patients. Maternal complications included gestational diabetes (2.3%), gestational hypertension (4.7%), cervical insufficiency (2.3%), and intrauterine fetal death (4.7%). Premature birth (< 37 weeks) occurred in 11.6% of cases, and 25.6% of newborns required NICU admission. Notably, 20.9% of patients had a history of intestinal surgery, and 37.1% received medications such as corticosteroids, antibiotics, or infliximab.
conclusionPregnant women with Crohn’s disease generally have favorable outcomes, especially when disease activity is well-controlled. Active disease during pregnancy, however, is associated with increased maternal and neonatal complications. Close monitoring and individualized management are crucial to optimizing pregnancy outcomes in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.